Acquisition of Shire Neuro

What will the upcoming acquisition of Shires Neuro division mean for Takeda’s future? On one hand you get 3 years left of Vyvance, Ituniv is a flop, but newly approved Mydayis could be a blockbuster. By next year there will be Takeda GI and Takeda CNS. Bigly changes ahead, get ready to make Takeda great again.

 

Wow. Now that’s far reaching. You pulled that right out of your ass.

 

Aren’t we already GI and CNS - by GI you are meaning the Entyvio side only? Are we back
to the rumor of “primary care” being dissolved ??

 

Nothing on the internet to support this acquisition. Where did you get this? A dream? Or inside info?

 

Ok, to the original poster, get your facts right...
Vyvanse, not Vyvance, and it’s an established product that doesn’t need a sales force.
Intuniv did 400 million a year (flop?) but is now generic.
You (original poster) will be perfect candidate to sell these drugs here in the US...

 

this is a complete joke. Shiré won’t give up Vyvanse, it’s a cash cow at the end of its cycle. Mydayis is a ‘me too’ adhd drug with shitty coverage and there is nothing left in their pipe. Well, I take that back it’s probably perfect for us then.

 

False Flag Post!

Takeda became great again with the 2017 layoff!

 

And Takeda will be even greater after the 2018 layoff.

 

maybe...decision is made either way. Whatever they think will make more profit for the stock holders. Corporate Life...

 

The original poster is full of BS! Shire announced they are keeping the CNS side as a separate unit. Nice try asshole!

 

I have heard this rumor also. I heard that the hope is to keep CNS in primary care as well as specialty, and to transition GI to specialty only. Who knows.

 

told ya! This could be great.

 

Well played

 

you earned your gloating privileges and they should not be denied!

 

Christophe's email this morning at 6:43AM is all about the possible acquisition of Shire, again POSSIBLE - not certain. Beyond that he hypes Vision 2025, and how profitable we are right now. You have to assume that end of year (3-30-18) layoffs are now off the table, but depending on how the acquisition shakes out, we could be sitting by the phone again in the very near future, so don't get too comfy.

 

Takeda doesn’t have the money nor market valuation to purchase shire. At best they could merge which would just mean a massive layoff also. The days of primary care reps are coming to an end.....if anything you’ll see primary care reps covering massive territories.

 

dont be so sure of it, Shire bought Baxalta and they are swimming in debt. You never know what could actually happen.

 

No way Takeda is stupid enough to buy the whole thing, 33 percent is added automatically to stock price for purchase or. Acquisition. They want the whole thing. Ok, you gonna borrow 73 billion dollars to acquire a company that has net profits of 7.3 billion a year? Remember, Vyvanse the third largest drug in the world, goes generic in 2024, and hemophilia has like a 50 percent mkt share and is facing immediate competition in the near future. Shire making 7.3 billion in profits by 2025 is a stretch. At best, they make a cheap big to try to get everything at a huge discount, or they buy rare disease only.

 

Its a done deal. Takeda reps heads will roll.Need to offset purchase with RIFs

 

Buh Bye Takeda primary care